Incorporating future unrelated medical costs in cost-effectiveness analysis in China

The occurrence of future unrelated medical costs is a direct consequence of life-prolonging interventions, but most pharmacoeconomic guidelines recommend the exclusion of these costs. The Chinese guidelines were updated in 2020, taking an exclusion approach for the future unrelated medical cost. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shan, Wang, Yitong, Zhou, Junwen, Jiang, Yawen, Liu, Gordon G, Wu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549663/
https://www.ncbi.nlm.nih.gov/pubmed/34702751
http://dx.doi.org/10.1136/bmjgh-2021-006655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549663/
https://www.ncbi.nlm.nih.gov/pubmed/34702751
http://dx.doi.org/10.1136/bmjgh-2021-006655

Ejemplares similares